BioCentury
ARTICLE | Clinical News

Intranasal naloxone: Phase I started

September 30, 2013 7:00 AM UTC

Lightlake began a Phase I trial to evaluate intranasal naloxone for 2 weeks in 14 healthy volunteers. The company is conducting the trial with NIH's National Institute on Drug Abuse (NIDA). Intranasal...